Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Summit Therapeutics to Participate in Upcoming Investor Conferences

By: Nasdaq / GlobeNewswire - 22 Nov 2017

Back to overview list

Summit Therapeutics plc
("Summit", or the "Company")

SUMMIT THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

Oxford, UK, 22 November 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, announces that management will participate in two upcoming investor conferences in New York City, US.

29 ^th Annual Piper Jaffray Healthcare Conference - November 28, fireside chat at 1:30pm EST
Oppenheimer Rare Disease Day - December 5

A live audio webcast of the Piper Jaffray fireside chat will be available through the Investors section on the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation. For the Oppenheimer Rare Disease Day, the Company will participate in one on one meetings.

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit
Glyn Edwards / Richard Pye (UK office)	Tel:	44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office)		+1 617 225 4455

Cairn Financial Advisers LLP (Nominated Adviser)	Tel:	+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson

N+1 Singer (Joint Broker)	Tel:	+44 (0)20 7496 3000
Aubrey Powell / Jen Boorer

Panmure Gordon (Joint Broker)	Tel:	+44 (0)20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking

MacDougall Biomedical Communications (US)	Tel:	+1 781 235 3060
Karen Sharma		ksharma@macbiocom.com

Consilium Strategic Communications (UK)	Tel:	+44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart /		summit@consilium-comms.com
Jessica Hodgson / Philippa Gardner

-END-

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Summit Therapeutics plc via GlobeNewswire

HUG#2151303

Related companies:

Summit Corporation plc | Summit Medical Products, Inc. | Great Summit Co., Ltd | Summit Biosciences Inc.

Back to overview list

to the top ↑